Inotiv logo
NOTVInotiv
Trade NOTV now
Inotiv primary media

About Inotiv

Inotiv (NASDAQ:NOTV) operates in the life sciences sector, offering products and services that span from discovery and preclinical research through clinical trial support. They specialize in providing comprehensive, integrated research solutions to help clients improve the efficiency and quality of their drug and medical device development efforts. Inotiv focuses on ensuring that their offerings are tailored to fit the evolving needs of the biopharmaceutical, medical device, and agrochemical industries. Their objective is to assist clients in accelerating their research and development timelines, optimizing their product development strategies, and ultimately enhancing patient care and agricultural production outcomes. With a commitment to innovation and client success, Inotiv strives to be a trusted partner in bringing novel treatments and solutions to market.

What is NOTV known for?

Snapshot

Public US
Ownership
1974
Year founded
2005
Employees
West Lafayette, United States
Head office
1 of 1
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Products and/or services of Inotiv

  • Comprehensive drug discovery and development services, offering integrated support from concept to clinical trials.
  • Nonclinical safety assessment, providing GLP-compliant toxicology studies for regulatory submissions.
  • Bioanalytical and analytical services, ensuring precise measurement of drug and metabolites in biological matrices.
  • Custom synthesis and manufacturing, offering chemical development services for small and large molecules.
  • Discovery pharmacology, aiding in target validation and efficacy evaluation for new compounds.
  • Regulatory and scientific consulting, guiding clients through complex drug development and regulatory processes.

Inotiv executive team

  • Mr. Robert W. Leasure Jr.President, CEO & Director
  • Ms. Beth A. Taylor CPAEVP & CFO
  • Ms. Andrea CastetterEVP of General Counsel & Corporate Secretary and Chief Compliance Office
  • Dr. John E. Sagartz D.V.M., DiplomateACVP, Ph.D.Chief Strategy Officer & Director
  • Dr. Adrian Hardy Ph.D.Chief Commercial Officer
  • Mr. Brennan FreemanVP of Finance, Principal Accounting Officer & Corporate Controller
  • Mr. Jeffrey Arthur KruppChief Human Resources Officer
  • Mr. John Gregory Beattie DSAChief Operating Officer of DSA
  • Ms. Lizanne MullerGroup President of RMS

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.